Skip to content

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03440697
Acronym
TAA
Enrollment
3000
Registered
2018-02-22
Start date
2015-12-10
Completion date
2030-12-31
Last updated
2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Disease, Aortopathies, Arterial Tortuosity Syndrome, Ascending Aortic Aneurysm, Ascending Aortic Disease, Autosomal Recessive Cutis Laxa, Bicuspid Aortic Valve, Bicuspid Aortic Valve-Associated Aortopathy, Congenital Contractural Arachnodactyly, Descending Aortic Aneurysm, Descending Aortic Disease, Familial Thoracic Aortic Aneurysm and Aortic Dissection, Loeys-Dietz Syndrome, Marfan Syndrome, PHACE Syndrome, Shprintzen-Goldberg Syndrome, Thoracic Aortic Aneurysm, Thoracic Aortic Disease, Thoracic Aortic Dissection, Thoracic Aortic Rupture, Turner Syndrome, Vascular Ehlers-Danlos Syndrome

Keywords

Cardiac Disease, Cardiovascular Genetics

Brief summary

The main purpose of this study is to define the complex genetic and pathogenic basis of thoracic aortic aneurysm (TAA) and other forms of aortopathy and/or aortic valve disease by identifying novel disease-causing genes and by identifying important genetic modifiers for aortic and aortic valve disease severity.

Detailed description

Thoracic aortic aneurysm (TAA) is a type of aortopathy describing dilation of the proximal aortic dimensions including the aortic root, which is a risk factor for aortic dissection and sudden cardiac death. TAA and other forms of aortopathy (e.g. aortic tortuosity or aortic hypoplasia/stenosis) develop in the presence or absence of additional cardiovascular malformations including bicuspid aortic valve. TAA is associated with connective tissue disorders (e.g. Marfan syndrome), and familial clustering has been identified in a significant proportion of nonsyndromic cases, establishing high heritability. Pedigree analysis of TAA kindreds clearly identifies complex inheritance; however, progress towards understanding the genetic basis of TAA and other forms of aortopathy and, ultimately, the susceptibility to aortic dissection remains incomplete. There is a clinical need to develop novel methods for predicting disease risk based on genotype and phenotype, to further elucidate the genetic and pathogenic mechanisms of aortopathy, and to improve medical and surgical therapies. The overarching hypothesis of this study is that individual genetic variation modulates susceptibility to disease severity and progression. The goals of this study are 1) to ascertain a cohort of subjects who have aortopathy and/or aortic valve disease including TAA or who have genetic risk for the development of aortopathy and/or aortic valve disease, 2) to collect paired blood and tissue samples from well-characterized subjects, family members of subjects, and controls to perform genome-wide DNA sequence, histopathologic, transcriptional, and proteomic analyses, and 3) to establish a tissue biorepository with detailed phenotype information to facilitate a broad spectrum of current and future studies.

Interventions

None listed

Sponsors

Yale University
Lead SponsorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Open to external enrollment: * Subjects with a genetic diagnosis of Marfan Syndrome (MDS), Loeys-Dietz Syndrome (LDS), or Vascular Ehlers-Danlos Syndrome (EDS); (Positive genetic testing or a previous cardiac study required to be eligible) * Family members of eligible subjects (Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time) * Closed to external enrollment: * Subjects with aortic disease including TAA\* or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) * Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease) * Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)

Exclusion criteria

• Inability or unwillingness to provide consent (assent when indicated)

Design outcomes

Primary

MeasureTime frameDescription
Biorepository Establishment20 yearsEstablish a biorepository with detailed phenotype information to facilitate a broad spectrum of current and future studies
Genetic Analysis20 yearsThe mechanisms of TAA pathogenesis will be determined by studying explanted aortic tissue and cells derived from patients with TAA for gene expression, protein expression, and other functional assays.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORBenjamin Landis, MD

Yale University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026